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A B S T R A C T   
Rett syndrome (RTT; OMIM#312750) is mainly caused by mutations in the X-linked MECP2 gene (methyl-CpG- 
binding protein 2 gene; OMIM*300005), which leads to impairments in the brain-derived neurotrophic factor 
(BDNF) signalling. The boost of BDNF mediated effects would be a significant breakthrough but it has been 
hampered by the difficulty to administer BDNF to the central nervous system. Adenosine, an endogenous neu-
romodulator, may accomplish that role since through A2AR it potentiates BDNF synaptic actions in healthy 
animals. We thus characterized several hallmarks of the adenosinergic and BDNF signalling in RTT and explored 
whether A2AR activation could boost BDNF actions. 
For this study, the RTT animal model, the Mecp2 knockout (Mecp2−/y) (B6.129P2 (C)-Mecp2tm1.1Bird/J) 
mouse was used. Whenever possible, parallel data was also obtained from post-mortem brain samples from one 
RTT patient. Ex vivo extracellular recordings of field excitatory post-synaptic potentials in CA1 hippocampal area 
were performed to evaluate synaptic transmission and long-term potentiation (LTP). RT-PCR was used to assess 
mRNA levels and Western Blot or radioligand binding assays were performed to evaluate protein levels. Changes 
in cortical and hippocampal adenosine content were assessed by liquid chromatography with diode array de-
tection (LC/DAD). 
Hippocampal ex vivo experiments revealed that the facilitatory actions of BDNF upon LTP is absent in 
Mecp2−/y mice and that TrkB full-length (TrkB-FL) receptor levels are significantly decreased. Extracts of the 
hippocampus and cortex of Mecp2−/y mice revealed less adenosine amount as well as less A2AR protein levels 
when compared to WT littermates, which may partially explain the deficits in adenosinergic tonus in these 
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animals. Remarkably, the lack of BDNF effect on hippocampal LTP in Mecp2−/y mice was overcome by selective 
activation of A2AR with CGS21680. 
Overall, in Mecp2−/y mice there is an impairment on adenosinergic system and BDNF signalling. These 
findings set the stage for adenosine-based pharmacological therapeutic strategies for RTT, highlighting A2AR as a 
therapeutic target in this devastating pathology.   
1. Introduction 
Rett Syndrome (RTT) is a progressive genetic neurodevelopmental 
disorder characterized by cognitive and motor impairments, develop-
ment of stereotypic hand movements and epilepsy. A developmental 
regression with loss of skills acquired during an apparently normal 
period after birth (ca. 6 months) is typical (Neul et al., 2014). RTT af-
fects 1:10.000 female live births worldwide and it is the main genetic 
cause of intellectual disability in girls (Chahrour and Zoghbi, 2007). 
About 90% of RTT cases are caused by mutations in methyl-CpG 
binding protein 2 gene (MECP2), located on the X chromosome, re-
sponsible for encoding the MeCP2 protein (Amir et al., 1999; Liyanage 
and Rastegar, 2014). This protein is an essential epigenetic factor that 
regulates the expression of several genes (Bedogni et al., 2014; Lewis 
et al., 1992; Liyanage and Rastegar, 2014). One of the genes under the 
jurisdiction of MeCP2 is the brain-derived neurotrophic factor (BDNF) 
gene, which encodes the neurotrophin BDNF (Li and Pozzo-Miller, 
2014). BDNF plays essential functions during neuronal development 
and maturation, including axonal targeting, dendritic growth, synaptic 
maturation and it is also a modulator of synaptic plasticity (Binder and 
Scharfman, 2004). Its actions are mediated by the high-affinity Tro-
pomyosin receptor kinase B full-length (TrkB-FL) receptors. BDNF 
binding to TrkB-FL receptors induces receptor dimerization and kinase 
domain transactivation, subsequently leading to activation of specific 
signalling transduction pathways (Huang and Reichardt, 2003). BDNF 
also has affinity to TrkB truncated isoforms (TrkB-Tc), which act as 
negative effectors of full-length receptors through their own pathways 
(Eide, 1996; Rose et al., 2003). 
Previous studies have shown that BDNF levels are decreased in RTT 
mouse models; thus, deregulation of BDNF functions in RTT has been 
suggested as a disease mechanism for the deficits in synaptic trans-
mission and plasticity, neuronal survival and development (Asaka et al., 
2006; Deng et al., 2007; Li et al., 2012; Li and Pozzo-Miller, 2014;  
Moretti et al., 2006; Robinson et al., 2012). Accordingly, BDNF mRNA 
levels were shown to be decreased in post-mortem brain samples from 
human patients (Abuhatzira et al., 2007). However, no changes were 
detected in BDNF protein levels on cerebrospinal fluid and blood serum 
samples (Riikonen, 2003; Vanhala et al., 1998). Experiments where 
BDNF expression levels were genetically manipulated in RTT mouse 
models have shown that BDNF overexpression led to symptomatic im-
provements (Chen et al., 2007; Guy et al., 2007, for review see Li and 
Pozzo-Miller, 2014). However, therapeutic designs involving BDNF 
delivery to the brain are still inefficient, given BDNF's inability to cross 
the blood-brain barrier (Poduslo and Curran, 1996). In order to over-
come this limitation, novel strategies should be considered, including 
the use of small molecules able to boost BDNF actions. 
It is now currently accepted that most BDNF actions are dependent 
on the activation of a specific type of adenosine receptors, the A2A re-
ceptors (A2AR) (Sebastião et al., 2011). On the other hand, another 
subtype of adenosine receptor, the A1R, has well known inhibitory 
actions upon synaptic transmission with impact in epilepsy control 
(Rombo et al., 2014). Modulation of adenosine receptors, mostly A1 and 
A2AR has long been considered as a useful strategy to treat several 
neurologic disorders, such as sleep disorders, epilepsy and neurode-
generative diseases (Sebastião and Ribeiro, 2009), but has never been 
tested in RTT. Modulators of adenosine receptors were already tested in 
clinical trials for treatment of other diseases (Chen et al., 2007). In light 
of the knowledge on: i) the cross-talk between BDNF and adenosine 
receptors, ii) the advantages of potentiating BDNF actions in RTT, and 
iii) the deregulation of the adenosinergic system in several pathological 
conditions co-occurring with epilepsy, we hypothesized that adenosine 
receptors could be therapeutic targets in RTT. To tackle this hypothesis, 
we used a well-recognized RTT mice model, the Mecp2 knockout 
(Mecp2−/y), to identify putative changes in the adenosinergic system 
and to assess whether pharmacological modulation of adenosine re-
ceptors could potentiate BDNF effects in this RTT model. 
2. Materials and methods 
2.1. Animals 
Experiments were performed in a mouse model of RTT 
(B6.129P2)C)-Mecp2tm1.1Bird/J [MECP2 knockout; Mecp2−/y], JAX 
#003890; (Guy et al., 2001) during the symptomatic stage (males be-
tween 6 and 10 weeks old; females between 26 and 28 weeks); wild 
type (WT) littermates were used as control. The genotype of animals 
was determined by PCR analysis, as previously described (Guy et al., 
2007). The animals were housed on a 12 h light/dark cycle, with food 
and water provided ad libitum. Throughout the experimental work, care 
was taken to minimize the number of animals sacrificed. All animals 
were handled according to the Portuguese law on Animal Care and 
European Community guidelines (86/609/EEC). Mice were sacrificed 
by decapitation under deep isoflurane anaesthesia. 
2.2. Post-mortem human brain sample 
The brain tissue of one 11 year-old girl with RTT (MeCP2 mutation - 
R255X) who died after a severe pneumonia was dissected and different 
anatomic regions were immediately frozen at −80 °C. Age- and sex- 
matched cortical tissue was kindly provided by the “Biobank de 
Hospital Infantil Sant Joan de Déu (HSJD) per la Investigació” in-
tegrated in the “Spanish Biobank Network of ISCIII for the sample and 
the data procurement”, to whom we are indebted. 
2.3. Ex vivo electrophysiological recordings 
After decapitation, the mouse brain was quickly removed, hemi-
sected and both hippocampi were dissected free within ice-cold artifi-
cial cerebrospinal fluid (aCSF) solution: NaCl 124 mM; KCl 3 mM; 
NaH2PO4 1.25 mM; NaHCO3 26 mM; MgSO4 1 mM; CaCl2 2 mM; and 
glucose 10 mM, previously gassed with 95% O2 and 5% CO2, pH 7.4. 
Slices (400 μm thick) were cut perpendicularly to the long axis of the 
hippocampus with a McIIwain tissue chopper and allowed to recover 
functionally and energetically for at least 1 h in a resting chamber, filled 
with aCSF, at room temperature. Slices were then transferred to a 
submerging chamber (1 ml) and continuously superfused at 3 ml/min 
with gassed aCSF at 32 °C; drugs were added to this superfusion solu-
tion. Field excitatory postsynaptic potentials (fEPSPs) were recorded 
extracellularly through a microelectrode (2–8 MΩ resistance, Harvard 
apparatus Ltd., Cambridge, MA, USA) placed in stratum radiatum of 
hippocampal CA1 area. One or two pathways (as indicated) of the 
Schaffer collateral/commissural fibers were stimulated (rectangular 
0.1 ms pulses), every 15 s (for input-output [I/O] curves and basal sy-
naptic transmission) or every 20 s (for long-term potentiation [LTP] 
recordings) through a bipolar concentric electrode placed on the 
Schaffer fibers, in stratum radiatum near CA3–CA1 border. The intensity 
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of stimulus (80–200 μA) was initially adjusted to obtain a large fEPSP 
slope with a minimum population spike contamination. The averages of 
8 (for I/O curves and basal synaptic transmission) or 6 (for LTP re-
cordings) consecutive responses were obtained and the slope of the 
initial phase of the potential was quantified. Recordings were obtained 
with an Axoclamp 2B amplifier (Axon Instruments, Foster City, CA, 
USA), digitized and continuously stored on a personal computer with 
the LTP software (Anderson and Collingridge, 2001). 
2.3.1. Basal synaptic transmission 
Alteration in synaptic transmission induced by drugs was evaluated 
as the % change in the average slope of the fEPSP in relation to the 
average slope of the fEPSP measured during the 10 min that preceded 
the addition of drugs to the superfusion solution, as described pre-
viously (Diógenes et al., 2004). 
(caption on next page) 
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2.3.2. LTP induction and quantification 
fEPSPs were elicited and recorded as outlined above. Stimulation 
was delivered alternatively to two independent pathways (Fig. 1A). LTP 
was induced by a θ-burst protocol consisting of three trains of 100 Hz, 
three stimuli, separated by 200 ms as previously described (Diógenes 
et al., 2011). LTP was quantified as the % change in the average slope of 
the fEPSP taken from 50 to 60 min after LTP induction in relation to the 
average slope of the fEPSP measured during the 10 min that preceded 
the induction of LTP. In each individual experiment, the same LTP-in-
ducing paradigm was delivered to each pathway. At 1 h after LTP in-
duction in one of the pathways, BDNF (20 ng/ml) was added to the 
superfusion solution and LTP was induced in the second pathway, no 
less than 20 min after BDNF perfusion and only after stability of fEPSP 
slope values was observed for at least 10 min (Fig. 1B). The effect of 
BDNF upon LTP was evaluated by comparing the magnitude of LTP in 
the first pathway in the absence of BDNF (control pathway), with the 
magnitude of LTP in the second pathway in the presence of BDNF (test 
pathway); each pathway was used as control or test on alternate days. 
The same experimental protocol was used to test the effect of 
CGS21680, an A2AR agonist, on LTP magnitude. In order to test the 
modulatory effect of A2AR activation on BDNF effect upon LTP, 
CGS21680 was added 60 min after LTP induction in the first pathway 
and at least 20 min before BDNF were added to the superfusion bath. 
Thus, in these experiments, LTP was induced in the second pathway in 
the presence of both CGS21680 and BDNF. These drugs remained in 
bath until the end of the experiment. 
2.3.3. Input–output curve (I/O) 
After obtaining a stable baseline for at least 10 min, the stimulus 
delivered to the slice was decreased until no fEPSP was evoked and 
subsequently increased in 20 μA steps. For each stimulation intensity, 
data from three consecutive averages of 8 fEPSP were collected. Inputs 
delivered to slices typically ranged from 60 μA to a supramaximal sti-
mulation of 320 μA. The input–output curve was plotted as the re-
lationship of fEPSP slope vs stimulus intensity, which provides a mea-
sure of synaptic efficiency as previously described (Diogenes et al., 
2012). 
2.4. Western Blot 
Snap-frozen cortex and hippocampus samples from mice of each 
genotype (WT and Mecp2−/y) were first disrupted with a Teflon pestle 
in Radio-Immunoprecipitation Assay (RIPA) buffer containing: 50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM ethyl-enediamine tetra-acetic 
acid (EDTA), 0.1% SDS and 1%Triton X-100 and protease inhibitors 
cocktail (Mini-Complete EDTA-free; Roche Applied Science, Penzberg, 
Germany). All lysates were then vortexed and sonicated (3 cycles of 
15 s), and clarified by centrifugation (13,000 g, 10 min). The protein 
content in the supernatant was determined by Bio-Rad DC reagent, a 
commercial Bradford assay (Sigma-Aldrich, St. Louis, MO, USA). Equal 
amount of protein was loaded (70 μg, except for A2AR blot: 200 μg) and 
separated on 10% sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride 
(PVDF) membrane (GE Healthcare, Buckinghamshire, UK). To check 
protein transfer efficiency, membranes were stained with Ponceau S 
solution. After blocking with a 5% non-fat dry milk solution in TBS- 
Tween (20 mM Tris base, 137 mM NaCl and 0.1% Tween-20), mem-
branes were incubated with the primary antibody, diluted in 3% BSA 
solution in TBS-Tween (overnight at 4 °C) and then with secondary 
antibodies HRP-conjugated (1:10000, Santa Cruz Biotechnology, 
Dallas, TX, USA) diluted in blocking solution (1 h at room temperature). 
Immunoreactivity was visualized using ECL chemiluminescence detec-
tion system (Amersham-ECL Western Blotting Detection Reagents from 
GE Healthcare) and band intensities were quantified by digital densi-
tometry (ImageJ 1.45 software). α-tubulin (1:3000, #ab4074, Abcam, 
Cambridge, MA, USA) or GAPDH (1:5000, #AM4300, Ambion by life 
technologies, Carlsbad, CA, USA) bands were used as loading control. 
The primary antibodies used were Anti-A2AR from Merk Millipore 
(1:1500, 05–717, Darmstadt, Germany) (Rei et al., 2020), Anti-A1R 
from Santa Cruz Biotecnology (1:1000, sc-28,995, Dallas, TX, USA), 
Anti-TrkB from BD Transduction Laboratories (1:1500, 610,101, 
Franklin Lakes, NJ, USA) and Anti-ADK from Bethyl Laboratories 
(1:1500, A304-280A, Montgomery, TX, USA). 
2.5. Radioligand binding experiments 
1,3-[3H]-dipropyl-8-cyclopentylxanthine ([3H]DPCPX) binding 
studies were performed in cortical brain homogenates (40–80 μg pro-
tein per assay) of Mecp2−/y mice and WT littermates. [3H]DPCPX 
binding was performed in an incubation solution (50 mM Tris-HCl 
buffer and 10 mM MgCl2 (pH 7.4) and 4 U/ml ADA) for 120 min at 
room temperature, in a final volume of 200 μl. Specific binding was 
calculated by subtraction of the nonspecific binding, defined in the 
presence of 2 μM XAC. The reaction was stopped by addition of cold 
incubation buffer and vacuum filtration through glass fiber filters 
(FilterMAT for receptor binding, Skatron Instruments, Mountain View, 
CA, USA) using a semiautomatic cell harvester from Skatron 
Instruments. The samples were then transferred to scintillation vials 
and radioactivity was measured by a liquid scintillation analyser (Tri 
Carb 2900TR, Perkin-Elmer, IL). Membrane protein content was mea-
sured using the Bio-Rad DC reagent, a commercial Bradford assay 
(Berkeley, CA, USA). 
2.6. RNA extraction and qPCR 
Total RNA was extracted from cerebral cortex samples of Mecp2−/y 
mice, WT littermates and human samples using RNeasy Lipid Tissue 
Mini Kit (Qiagen, Venlo, Netherlands), according to the manufacturer's 
instructions. RNA concentration and purity were then evaluated by 
spectrophotometry based on optical density (OD) measurements at 260 
Fig. 1. BDNF loses the facilitatory effect upon LTP in Mecp2−/y animals: A shows schematic representation of a transverse hippocampal slice and the recording 
configuration used, as described in methods section. B represents the protocol used to evaluate the effect of BDNF upon LTP (see methods). Panels C and D show time 
courses of averaged changes in fEPSP slope induced by the θ-burst stimulation in the absence (light circles) or in the presence (dark circles) of BDNF in hippocampal 
slices taken from WT (grey symbols,n = 5) animals or from Mecp2−/y (blue symbols,n = 5) animals. Traces from representative experiments are shown for WT and 
Mecp2−/y animals. Histogram E depicts the magnitude of LTP in the absence (light bars) and the presence of BDNF (20 ng/ml, dark bars) in hippocampal slices from 
WT (grey) or Mecp2−/y animals (blue). F shows the input/output (I/O) curves corresponding to responses generated by various stimulation intensities (60–340 μA) in 
WT slices (grey circles,n = 4) and Mecp2−/y slices (blue circles,n = 4). *p  <  0.05 (paired Student's t-test) as compared with absence of BDNF in the same ex-
periments. 
In H,I and M are shown the averaged of TrkB-FL(WThip,n = 13;WTctx,n = 14;Mecp2−/yhip ,n= 12;Mecp2−/yctx ,n=13), TrkB-Tc (WThip, n = 14;WTctx,n = 14;Mecp2−/ 
y
hip,n = 13;Mecp2−/yctx ,n = 14) and BDNF(WThip,n = 8;WTctx,n = 8;Mecp2−/yhip ,n = 9;Mecp2−/yctx ,n = 6) density evaluated by Western-Blot analysis in hippocampal 
and cortical homogenates from WT(grey) and Mecp2−/y(blue) animals with 6–10 weeks of age. G and L show representative bands obtained by Western Blot for each 
studied protein. All values presented are mean  ±  SEM and are represented in % of WT protein. J,K and NeP depicted data obtained by qPCR showing mRNA levels 
of TrkB-FL(J,O), TrkB-Tc(K,P) and BDNF(N) in cortical samples from WT(light bar,n = 5) and Mecp2−/y(dark bar,n = 5) animals (J and K) and from a human 
temporal cortex sample (N,O and P) taken from a control patient (white bar,n = 1) and a RTT patient (black bar,n = 1). All values are mean  ±  standard error of 
mean (SEM). *p  <  0.05; **p  <  0.01; ***p  <  0.001 (Student's t-test); #p  <  0.05 (F test). 
C. Miranda-Lourenço, et al.   Neurobiology of Disease 145 (2020) 105043
4
and 280 mm (Model: NanoDrop-100; Thermo Scientific, Rockford, IL, 
USA). cDNA synthesis was performed in a 20 μl reaction mixture. 2 μg 
of total RNA were mixed with 1 μl random primer hexamers (Amersham 
Life Sciences, Buckinghamshire, UK) and 1 μl (each) of dATP, dTTP, 
dCTP and dGTP (10 mM). This mix was incubated 5 min at 65 °C and 
after cooling for 2 min on ice, the remaining reagents were added (4 μl 
of 25 mM MgCl2, 2 μl of 10× RT buffer, 2 μl of 0.1 M DTT, 0.5 μl 
Superscript II Reverse Transcriptase (200 U); all reagents from 
Invitrogen, Life Technologies, Waltham, MA, USA). Parallel reactions 
for each RNA sample were run without Superscript II to evaluate the 
degree of genomic DNA contamination. Gene expression level was ad-
dressed by quantitative PCR (qPCR) using Power SYBR® Green Master 
Mix (Life Technologies, Waltham, MA, USA), and cDNA was used as 
template for the real-time PCR run in Rotor Gene 6000 (Corbett Life 
Science, Uithoom, Netherlands). Negative control PCR samples were 
run with no template. Relative mRNA expression was calculated using 
2-Δct method and primers were previously optimized in order to es-
tablish annealing temperature and primer efficiency (e = 2  ±  0.2), 
calculated after serial primer dilutions and construction of respective 
standard curve (slope and R2 respectively around −3.3 and 0.99; de-
scribed in Schmittgen and Livak, 2008). Data were normalized to the 
expression of PPIA peptidylprolyl isomerase A (cyclophilin A) (CypA) 
and ribosomal protein L13A (Rpl13A) (Batalha et al., 2016). The 5′-3′ 
primer sequences used for Cyp A (125 bp) were TAT CTG CAC TGC CAA 
GAC TGA GTG (forward) and CTT CTT GCT GGT CTT GCC ATT CC 
(reverse); for Rpl13A (130 bp) were GGA TCC CTC CAC CCT ATG ACA 
(forward) and CTG GTA CTT CCA CCC GAC CTC (reverse); for A2AR 
(113 bp) were ATT CCA CTC CGG TAC AAT GG (forward) and AGT TGT 
TCC AGC CCA GCA T (reverse) (Batalha et al., 2016); for A1R (155 bp) 
were TCG GCT GGC TAC CAC CCC TTG (forward) and CCA GCA CCC 
AAG GTC ACA CCA AAG C (reverse); for TrkB-FL were GAG CTG CTG 
ACC AAC CTC CA (forward) and GTC CCC GTG CTT CAT GTA CTC A 
(reverse); for TrkB-T1 were TAA GAT CCC ACT GGA TGG GTA G 
(forward) and AAG CAG CAC TTC CTG GGA TA (reverse) (Karpova 
et al., 2014). Data acquisition was performed with Rotor-Gene Series 
Software 1.7 (Corbett Life Science) and data analysis was performed 
with Microsoft Excel, Office 2016, Redmond, WA, USA. For human 
brain cortex samples, the real time-PCR was run in 7500 Fast (Applied 
Biosystems, Foster City, CA, USA) and the normalization was done to 
GAPDH expression. Data acquisition was performed with 7500 software 
v2.0.6 (Applied Biosystems, Foster City, CA, USA) and data analysis was 
performed in Microsoft Excel, Office 2016, Redmond, WA, USA. The 5′- 
3′ primer sequences used for GAPDH were GGA GCT AAC GGA TTT 
GGT CG (forward) and GAC AAG CTT CCC GTT CTA G; for A2AR were 
AAC CTG CAG AAC GTC AC (forward) and GTC ACC AAG CCA TTG 
TAC CG (reverse) (Batalha et al., 2016); for A1R were GCC ACA GAC 
CTA CTT CCA CA (forward) and CCT TCT CGA ACT CGC ACT TG (re-
verse); for TrkB-FL were GGC CCA GAT GCT GTC ATT AT (forward) and 
TTC TGC TCA GGA CAG AGG TT (reverse) (Nicolini et al., 2015); for 
TrkB-T1 were TCT ATG CTG TGG TGG TGA TTG (forward) and GAG 
TCC AGC TTA CAT GGC AG (reverse) (Luberg et al., 2010). 
2.7. Extraction and analysis of purines by liquid chromatography with 
diode array detection (LC/DAD) 
The purines (ATP, AMP, adenosine and inosine) content of extracts 
from the cortex and hippocampus of WT and Mecp2−/y mice was 
measured by liquid chromatography with diode array detection (LC/ 
DAD). Snap-frozen cortex and hippocampal tissue samples were stored 
at −80 °C until use. For extraction, the samples were defrosted (250 μl) 
in round-bottom microcentrifuge tubes followed by thorough tissue 
homogenization using a mixture of ice-cold acetonitrile: methanol: 
water (1:2:2) solution (Jackson et al., 2017) containing 2-chloro-ade-
nosine (5 μM) as internal standard; the obtained mixture was cen-
trifuged at 16000 g for 20 min at 4 °C. Tissue homogenization and 
centrifugation were repeated twice. The two recovered supernatant 
extracts (~250 μl each) were mixed together and, then, centrifuged 
again at 16000 g (for 20 min at 4 °C) using a 50-kDa cutoff filter 
(Amicon Ultra-0.5 50 K Filter Device; Merck KGaA, Darmstadt, Ger-
many). After filtration, supernatant extracts were divided in 15-μl ali-
quots and stored at −80 °C until analysis. Using this procedure, re-
covery of adenine nucleosides was higher than 95%, as determined by 
adding 2-chloro-adenosine (5 μM) as internal standard before extrac-
tion. 
Extraction media containing purines were 1/10 diluted with water 
before LC/DAD analysis. Chromatographic separation of nucleosides 
was carried out using an elution gradient composed of ammonium 
acetate (5 mM, with a pH of 6 adjusted with acetic acid) and methanol 
(Silva et al., 2020, 2017; Vieira et al., 2017). Separation of adenine 
nucleotides was carried using a paired-ion chromatography reagent 
(PIC Reagent A; Waters Chromatography Europe BV, Etten-Leur, The 
Netherlands) containing tetrabutylamonium phosphate (1 mM) in 
KH2PO4 (100 mM, at pH = 6) (Waters) and methanol. Separation of 
adenine nucleotides and nucleosides using both elution systems was 
achieved by reversed–phase liquid chromatography through a Hypersil 
GOLD C18 column (5 μM, 2.1 mm × 150 mm) equipped with a guard 
column (5 μm, 2.1 mm × 1 mm) and assayed using a Finigan Thermo 
Fisher Scientific System LC/DAD, equipped with an Accela Pump cou-
pled to an Accela Autosample, a diode array detector and an Accela 
PDA running the X-Calibur software chromatography manager. Quan-
tification of adenine nucleotides and nucleosides was carried out using 
calibration curves made of high-purity external standards, namely ATP, 
AMP, adenosine and inosine. 
2.8. Drugs 
BDNF was generously provided by Regeneron Pharmaceuticals; 2- 
[p-(2-carboxyethyl)phenethylamino]-50-N-ethylcarboxamido adeno-
sine (CGS21680) was purchased from Sigma; N6-Cyclopentyladenosine 
(CPA) and 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX) were pur-
chased from Tocris Bioscience (Ballwin, MO, USA); 1[3H]DPCPX was 
purchased from American Radiolabeled Chemicals, Inc.; ATP, AMP, 
adenosine, inosine, 2-chloro-adenosine and 5-iodotubercidin (ITU) 
were purchased from Sigma (St. Louis, MO, USA). BDNF was supplied 
in a 1.0 mg/ml stock solution in 150 mM NaCl, 10 mM sodium phos-
phate buffer, and 0.004% Tween 20. CGS21680, CPA and DPCPX were 
made up in 5 mM and ITU in 50 mM stock solutions in DMSO. [3H] 
DPCPX was purchased as a 36.5 μM solution in ethanol. The maximum 
DMSO concentration (0.02%) applied to the preparations was devoid of 
action on fEPSPs (Tsvyetlynska et al., n.d.). Aliquots of the stock solu-
tions were kept frozen at −20 °C until use. 
2.9. Data analysis 
The data are expressed as mean  ±  SEM of the n number of in-
dependent experiments. The significance of differences between the 
means of 2 conditions was evaluated by paired or unpaired t-tests; 
Welch correction was used in unpaired t-test as appropriate. Nonlinear 
regressions were used to fit data pertaining I/O curves and radioligand 
binding experiments. Values of p  <  0.05 were considered to represent 
statistically significant differences. GraphPad Prism 5.00 was used to 
performed statistical analysis. 
3. Results 
3.1. BDNF does not increase the magnitude of LTP in the hippocampus of 
Mecp2−/y mice 
LTP is generally regarded as the neurophysiological correlate for 
learning and memory and BDNF has a well-documented ability to in-
crease its magnitude on hippocampal CA1 area through TrkB-FL re-
ceptors activation (Figurov et al., 1996; Minichiello et al., 1999). To 
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assess the functional impact of the decrease in BDNF levels in RTT (Li 
and Pozzo-Miller, 2014), we evaluated the effect of exogenously ap-
plied BDNF (20 ng/ml) upon LTP. As expected (Diógenes et al., 2011;  
Fontinha et al., 2008), the θ-burst paradigm applied to hippocampal 
slices, taken from wild type (WT) animals induced a robust LTP in the 
presence of BDNF (48.2  ±  4.5%, n = 5; Fig. 1C;E), which was 
significantly higher than the obtained in the absence of BDNF 
(27.5  ±  5.8%, n = 5; p = 0.02, paired t-test; Fig. 1C;E). Importantly, 
in the absence of BDNF, θ-burst stimulation induced a small, yet sig-
nificant LTP in WT mice (p = 0.009, paired t-test), but not in Mecp2−/y 
mice (p = 0.45, paired t-test). Moreover, BDNF (20 ng/ml) did not 
further increase LTP magnitude in hippocampal slices taken from 
Fig. 2. Extracellular levels of adenosine are decreased in Mecp2−/y mice. In fig. A and B the ordinates represent the amount of ATP, AMP, adenosine (ADO) and 
inosine (INO) in nmol extracted from the cortex and hippocampus, respectively, of WT (grey bars) and Mecp2−/y (blue bars) mice and detected by LC/DAD (for 
details, see Materials and Methods). Represented are box-and-whiskers plots, with whiskers ranging from minimum to maximum values; horizontal lines inside boxes 
indicate the corresponding medians. Each data point represents four to eight individuals (see text for details); duplicate measurements were performed for each 
individual experiment. p  <  0.05 (one-way ANOVA; uncorrected Fisher's LSD, with a single pooled variance) represent significant differences when compared to WT 
animals. The left panel of C shows the averaged time courses of changes in fEPSP slope induced by application of DPCPX (50 nM) in slices taken from WT (grey 
circles, n = 4) and Mecp2−/y (blue circles,n = 10) animals. The histogram on the right represent the averaged normalized decrease in fEPSPs slope in each animal 
group in response to DPCPX. D left panel shows the averaged time courses of changes in fEPSP slope induced by application of three different concentrations of CPA 
(3 nM, 10 nM, 30 nM) in slices taken from WT (grey circles,n = 7) and Mecp2−/y (blue circles,n = 7) animals. The right panel shows the comparison of the averaged 
effects of different concentrations of CPA in the different genotypes. Left panel of F shows the averaged time course of changes in fEPSP slope induced by ITU 
(100 nM) applied for 84 min. Hippocampal slices were taken from WT (grey circles,n = 7) and Mecp2−/y mice (blue circles, n = 6). The right panel shows the 
comparison of the averaged effects of ITU in the different genotypes. Left panel in E shows representative bands obtained by Western Blot of cortical and hippocampal 
tissue homogenates from Mecp2−/y and WT mice with 6–10 weeks of age. On the left panel, the histograms represent average band intensity for ADK obtained in 
samples from WT (grey bars,nhip = 11; nctx = 10) and Mecp2−/y (blue bars,nhip = 9; nctx = 10) hippocampal and cortical homogenates. All values presented are 
mean  ±  SEM and are represented in % of WT protein. *p  <  0.05 (Student's t-test). (For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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Mecp2−/y animals (LTPCTR = 10.2  ±  11.9%, LTPBDNF 14.5  ±  7.0%, 
n = 5; p = 0.72, paired t-test; Fig. 1D;E). 
To evaluate whether the impairment of LTP in Mecp2−/y animals 
could be due to changes in baseline synaptic efficiency, I/O curves were 
performed. Hippocampal slices taken from Mecp2−/y animals displayed 
higher Emax values when compared with WT animals 
(EmaxWT = 0.99  ±  0.04, n = 4; EmaxMecp2−/y = 1.78  ±  0.21, n = 4; 
p = 0.01, unpaired t-test; Fig. 1F). These data indicate higher neuronal 
excitability in the hippocampus of Mecp2−/y animals and that LTP 
impairment in Mecp2−/y animals is not due to a decrease in basal sy-
naptic transmission efficiency. 
3.2. BDNF and TrkB-FL receptor proteins are decreased in Mecp2−/y mice 
Previous data suggest that MeCP2 acts both as a repressor and as an 
activator of gene expression (Chahrour et al., 2008). Given that the 
BDNF gene is under MeCP2 transcriptional regulation (Chen et al., 
2003) attention has been directed to BDNF protein changes on RTT. Our 
results corroborate the previously described decrease in BDNF protein 
levels (for review see Li and Pozzo-Miller, 2014), both in the cerebral 
cortex and hippocampus (HIPWT = 100.0  ±  4.8%, n = 8 vs HIPMecp2−/ 
y = 75.0  ±  7.2%, n = 9, p = 0.01, unpaired t-test; CTXWT = 100.0  ±   
10.9%, n = 8 vs CTXMecp2−/y = 56.1  ±  3.7%, n = 6, p = 0.006, un-
paired t-test; Fig. 1M;L). 
However, the expression levels of TrkB-FL and its truncated isoform 
(TrkB-Tc), crucial players in BDNF mediated synaptic plasticity, had not 
yet been fully addressed. Therefore, we evaluated TrkB receptors levels 
in Mecp2−/y mice. As shown in Fig. 1G;H, TrkB-FL protein expression 
levels are decreased in both the cerebral cortex and the hippocampus of 
Mecp2−/y mice when compared to WT littermates (HIPWT = 100  ±   
5.6%, n = 13 vs HIPMecp2−/y = 70.0  ±  9.4%, n = 12; p = 0.01, un-
paired t-test; CTXWT = 100.0  ±  5.3%, n = 14 vs CTXMecp2−/ 
y = 66.2  ±  5.7%, n = 13, p = 0.0002, unpaired t-test; Fig. 1H). Re-
garding TrkB-Tc protein expression levels, no significant changes were 
detected (HIPWT = 100.0  ±  6.1%, n = 14 vs HIPMecp2−/y = 94.5  ±   
11.8%, n = 13, p = 0.67, unpaired t-test; CTXWT = 100.0  ±  4.0%, 
n = 14 vs CTXMecp2−/y = 83.7  ±  7.345%, n = 14, p = 0.06, unpaired 
t-test Fig. 1I). 
In addition, mRNA relative expression of both TrkB-FL and the most 
expressed TrkB-Tc (Luberg et al., 2010), TrkB-T1, were analysed by 
qPCR. As shown in Fig. 1J;K, no significant differences between WT and 
Mecp2−/y mice were detected (TrkB-FLWT = 0.12  ±  0.03, n = 5 vs 
TrkB-FLMecp2−/y = 0.18  ±  0.03, n = 5, p = 0.22, unpaired t-test; 
TrkB-T1WT = 0.18  ±  0.03, n = 5 vs TrkB-T1Mecp2−/y = 0.2  ±  0.04, 
n = 5, p = 0.39, unpaired t-test). Moreover, one post-mortem temporal 
cortex sample from a RTT patient was evaluated together with an aged- 
matched control. TrkB-FL mRNA expression in the temporal cortex of 
RTT patient showed a small increase (32.14%) when compared with the 
control (Fig. 1O). No apparent changes were observed regarding the 
mRNA expression levels of BDNF (Fig. 1N) and TrkB-Tc (Fig. 1P). 
3.3. The adenosinergic modulation of synaptic transmission is compromised 
in Mecp2−/y mice 
The lack of BDNF effect upon LTP could be explained by the de-
creased expression of TrkB-FL receptors in the hippocampus. However, 
since BDNF-induced facilitation of hippocampal LTP is tightly depen-
dent on the activation of A2AR by endogenously generated adenosine 
(Fontinha et al., 2008), we next characterized the adenosinergic system 
in Mecp2−/y mice. 
Brain extracts from Mecp2−/y mice exhibit lower (p  <  0.05) ade-
nosine amounts compared to WT animals in the cortex (WT =  
35.49  ±  4.04 nmol, n = 8 vs. Mecp2−/y = 20.60  ±  2.91 nmol; n = 9, 
p-value = 0.009, Welch's t-test, Fig. 2A) and in the hippocampus 
(WT = 9.62  ±  0.99 nmol, n = 8 vs. Mecp2−/y = 5.55  ±  0.92 nmol; 
n = 8, p-value = 0.023, Welch's t-test, Fig. 2B), without any measurable 
changes in the levels of inosine. These results suggest that adenosine 
deficiency in RTT animals might not be related to increases in adeno-
sine deaminase (ADA) activity. This prompted us to measure the 
amount of adenosine precursors (e.g. ATP and AMP) in the same sam-
ples. Brain extracts exhibit very small amounts of ATP, which levels did 
not differ among WT and Mecp2−/y mice both in the cortex 
(WT = 8.36  ±  1.77 nmol vs. Mecp2−/y = 6.34  ±  2.07 nmol; n = 4; 
p  >  0.05, Fig. 2A) and in the hippocampus (WT = 3.76  ±  1.77 nmol 
vs. Mecp2−/y = 2.19  ±  0.84 nmol; n = 4; p  >  0.05, Fig. 2B). Contra-
riwise, higher AMP amounts compared to adenosine were extracted 
from the cortex (57.88  ±  3.57 nmol; n = 4) and hippocampus 
(30.28  ±  3.12 nmol; n = 4) of WT animals, but these levels also sig-
nificantly (p  <  0.05) decreased to 41.19  ±  1.30 nmol (n = 4) and 
24.26  ±  2.64 nmol (n = 4) in the cortex and hippocampus of Mecp2−/ 
y mice, respectively (Fig. 2A;B). The observed increase in the proportion 
of AMP vis a vis adenosine in cortical and hippocampal extracts of 
Mecp2−/y mice may indicate a decrease in 5′-nucleotidase activity, the 
enzyme responsible for AMP dephosphorylation into adenosine, and/or 
a higher competence of intracellular adenosine kinase (ADK) mediating 
phosphorylation of adenosine back to AMP. Next, we set to test the 
functional repercussions of having lower adenosine amounts in the 
hippocampus of Mecp2−/y mice compared to WT littermates. If our 
prediction is correct, facilitation (disinhibition) of hippocampal sy-
naptic transmission produced by the selective A1R antagonist, DPCPX 
(Diogenes et al., 2014) should be less prominent in Mecp2−/y mice 
compared to WT animals. A supramaximal concentration of DPCPX 
(50 nM; Ki value of 0.5 nM in the hippocampus (Sebastião et al., 1990)) 
was used to evaluate the effect of A1R blockage on basal synaptic 
transmission in hippocampal slices from Mecp2−/y mice and WT lit-
termates. The magnitude of fEPSP slope in the presence of DPCPX 
(50 nM) was significantly higher in hippocampal slices from WT com-
pared to those obtained from Mecp2−/y mice (WT = 45.3  ±  10.1%, 
n = 4, vs. Mecp2−/y = 23.4  ±  4.4%, n = 10; p = 0.0374, unpaired t- 
test; Fig. 2C). 
Despite the reduction of the adenosine inhibitory tonus in hippo-
campal synaptic transmission in Mecp2−/y mice is in keeping with the 
observed low endogenous levels of the nucleoside in brain extracts (see 
above), A1R hypoactivity could also explain the results obtained. To 
sort this out, we tested the effect of the selective A1R agonist, CPA, at 
increasing concentrations (3, 10 and 30 nM). Exogenously added CPA 
concentration-dependently decreased fEPSP slope to a higher extent in 
Mecp2−/y mice compared to WT animals; this difference turn out to be 
significant (p  <  0.05) at the highest concentration tested (30 nM) 
(WT = 31.4  ±  5.9%, n = 7 vs. Mecp2−/y = 52.4  ±  6.530%, n = 7; p- 
value = 0.0345, unpaired t-test; Fig. 2D). These results (1) exclude the 
hypothesis that A1R are hypoactive in Mecp2−/y mice, (2) predict high 
expression rates of inhibitory A1R in the hippocampus of these animals, 
and (3) strengthens the theory that reduction of the inhibitory control 
of adenosine on hippocampal synaptic transmission in Mecp2−/y mice is 
mainly due to insufficient availability of the nucleoside at A1R sites. In 
the CNS, phosphorylation of adenosine leading to AMP formation by 
ADK is paramount to keep low intracellular levels of the nucleoside 
and, thus, it is considered the main driving force to take up adenosine 
from the extracellular milieu (Boison, 2013). Overexpression of ADK 
has been observed in astrocytes of epileptic brains of mice and humans 
(Aronica et al., 2011), which is consistent with the hypothesis that the 
pathophysiology of epilepsy involves lower endogenous adenosine le-
vels and, thus, a deficient inhibition of synaptic transmission (Boison, 
2013). Fig. 2E shows that the ADK protein level is not different in 
Mecp2−/y and WT mice, both in the hippocampus (HIPWT = 100.2  ±   
8.1%, n = 11 vs. HIPMecp2−/y = 107.4  ±  11.24%, n = 10, p = 0.60, 
unpaired t-test) and in the cerebral cortex (CTXWT = 100.0  ±  4.3%, 
n = 9 vs. CTXMecp2−/y = 98.5  ±  5.8%, n = 10, p = 0.84, unpaired t- 
test; Fig. 2E). It is, however, worth noting that Western Blot data re-
flects protein levels in whole tissue homogenates, not allowing the ac-
cess to cell-specific protein contents at the synaptic level. Inhibition of 
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ADK is often used to reverse the nucleoside gradient across the plasma 
membrane leading to adenosine outflow via equilibrative nucleoside 
transporters (ENT) and its, subsequent, extracellular accumulation (Lee 
and Chao, 2001; Li et al., 2012). Here, we tested the effect of the ADK 
inhibitor, 5-iodotubercidin (5-ITU) (Pak et al., 1994), on basal hippo-
campal synaptic transmission. As shown in Fig. 2F, 5-ITU (100 nM) 
decreased fEPSP slope in hippocampal slices of both Mecp2−/y mice and 
WT littermates, but the effect of the ADK inhibitor had a higher 
(P = 0.02, unpaired t-test) inhibitory magnitude in WT (48.0  ±  6.6%, 
n = 7) compared to Mecp2−/y (25.2  ±  5.3%, n = 6) animals. Data 
show that inhibition of ADK could not fully overcome adenosine defi-
ciency at the A1R level in the hippocampus of Mecp2−/y mice, thus 
indicating lower levels of endogenous adenosine. 
Fig. 3. A2AR protein expression is decreased and A1R is increased in Mecp2−/y mice: In A and B panels are shown the averaged A2AR receptors density while in D and 
F panels are shown the averaged A1R receptors density, all evaluated in hippocampal and cortical brain samples, respectively, by Western Blot analysis of WT (grey 
bar, nhipA2AR = 8; nctxA2AR = 6; and nhipA1R = 5; nctxA1R = 6) and Mecp2−/y (blue bars, nctxA2AR = 6; nhipA2AR = 8 and nctxA1R = 6; nhipA1R = 5) animals 6–10 weeks 
old. The results are represented in % of WT protein. In E are shown saturation isotherms for the binding of the selective A1R receptor antagonist [1H]DPCPX to the 
cortical homogenates of WT (grey circles,n = 5) and Mecp2−/y (blue circles,n = 6) animals. In C and G are shown histograms representing the relative qPCR data 
showing mRNA levels of A2AR and A1R, respectively, from cortical samples of WT (grey bar,n = 5) and Mecp2−/y mice (blue bar, n = 5). H and I histograms 
represent relative qPCR data showing mRNA levels of A1R and A2AR, respectively, present in temporal cortex from a healthy control (grey bar,n = 1) and from a 
human RTT patient (blue bar,n = 1). All values are mean  ±  standard error of mean (SEM). *p  <  0.05 (Student's t-test); #p  <  0.05 (F test). (For interpretation of 
the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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3.4. A2AR expression is decreased and A1R expression is increased in 
Mecp2−/y mice 
To further understand how the adenosinergic system is disturbed in 
Mecp2−/y mice, we evaluated the A1R and A2AR expression at mRNA 
and protein levels. A2AR protein levels were assessed by Western Blot 
using an antibody validated against A2AR KO samples (supplementary 
Fig. 5A). Western Blot analysis of cortical and hippocampal homo-
genates show that A2AR protein amounts are significantly decreased in 
Mecp2−/y mice cortex compared to WT littermates and show a tendency 
for decreased A2AR protein levels in the hippocampus (CTXWT =  
100.0%  ±  24.8, n = 6 vs CTXMecp2−/y = 37.5%  ±  11.3, n = 6; 
p = 0.04, unpaired t-test; and HIPWT = 100.00  ±  11.78%, n = 8 and 
HIPMecp2−/y = 82.19  ±  9.86%, n = 8; p = 0.258, unpaired t-test;  
Fig. 3A;B). Despite this, no significant differences were detected upon 
evaluating the A2AR mRNA relative expression in the two genotypes 
(WT = 0.017  ±  0.006, n = 5 vs. Mecp2−/y = 0.027  ±  0.005, n = 5, 
p = 0.26, unpaired t-test; Fig. 3C). 
The existence of commercially available high affinity/high se-
lectivity A1R ligands allowed us to perform receptor binding assays, 
which are frequently preferred (over Western Blot) for quantitative 
analysis of receptor expression whenever a considerable amount of 
tissue is available. Therefore, A1R were firstly evaluated by binding 
assays in cortical homogenates given the higher levels of protein con-
tent in this particular brain area. In Fig. 3E the saturation isotherms for 
the specific binding of the A1R antagonist, [3H]DPCPX, show that this 
ligand binds more extensively to cortical brain homogenates of 
Mecp2−/y mice than to their WT littermates. The Bmax value obtained by 
nonlinear regression analysis, a measure of A1R expression levels, was 
significantly higher for Mecp2−/y mice (WT = 127.9  ±  17.1 fmol mg/ 
protein, n = 5 vs. Mecp2−/y = 229.5  ±  22.1 fmol mg/protein, n = 6, 
p = 0.007, unpaired t-test). No significant differences in the Kd values, a 
measure of receptor binding affinity, were found among the two gen-
otypes (WT = 6.8  ±  2.7 nM, n = 5 vs. d Mecp2−/y = 4.3  ±  1.4 nM, 
n = 6, p = 0.42, unpaired t-test). By Western Blot technique similar 
data were obtained in cortex and hippocampus (HIPWT= 100.00  ±   
7.88%, n = 5 vs. HIPMecp2−/y = 119  ±  5.17,n = 5; p = 0.049, un-
paired t-test; Fig. 3D;F and CTXWT = 100.0  ±  6.34, n = 6 vs 
CTXMecp2−/y = 144  ±  17.81,n = 6; p = 0.041, unpaired t-test;  
Fig. 3D;F). Overall, data suggest that A1R expression levels are sig-
nificantly increased in the cortex and hippocampus of Mecp2−/y 
animals compared to WT littermates. This difference may be owe to 
post-translational protein modifications, given to the fact that qPCR 
assays revealed no significant changes in cortical mRNA A1R gene 
transcripts (WT = 0.027  ±  0.004, n = 5 vs. Mecp2−/ 
y = 0.025  ±  0.004, n = 5, p = 0.7, unpaired t-test; Fig. 3G). Interest-
ingly, analyses of the temporal cortex from a RTT patient revealed a 
mRNA expression profile that is more consistent with the results ob-
tained at the protein level in the mouse cortex, revealing an increase in 
A1R and a decrease in A2AR mRNA expression levels (Fig. 3H,I). The 
hippocampus of symptomatic heterozygous females (Het), where the 
phenotype is less severe, were also analysed (supplementary Fig. 5B). 
Similar changes in A1R and A2AR expression were detected in Het when 
compared to controls:1) significant decreased of A2AR protein levels in 
Het (WT = 100.00  ±  17.78%, n = 6 vs. Het = 52.47  ±  8.54%, n = 6, 
p = 0.04, unpaired t-test); 2) significant increase of A1R protein levels 
Het (WT = 100.00  ±  3.89%, n = 5 vs. Het = 116.60  ±  3.62%, n = 5, 
p = 0.01, unpaired t-test) supporting that adenosinergic system can be 
altered in several degrees of RTT severity. 
3.5. Exogenous activation of A2AR restores BDNF-induced LTP facilitation 
in Mecp2−/y mice 
The results reported above indicate that endogenous levels of adeno-
sine and, thus, the nucleoside-mediated control of synaptic transmission 
are both deficient in the hippocampus of Mecp2−/y mice, along with a 
concomitant reduction of A2AR protein expression in this brain region. 
Therefore, we hypothesized that reduced adenosine A2AR tonus could also 
contribute to impairment of BDNF-mediated actions in RTT patients. 
Indeed, a strong body of evidence demonstrates that several BDNF actions 
rely on the activation of A2AR (Sebastião et al., 2011). Furthermore, this 
cross-talk was shown to be dynamic, for instance, during aging where the 
reduction of TrkB-FL receptor levels is accompanied by increases in A2AR 
levels (Diogenes et al., 2007). This prompted us to investigate whether 
activation of A2AR could be a feasible strategy to overcome BDNF sig-
nalling deficits in RTT patients, along with the reduced levels of this 
neurotrophin and to the partial loss of its TrkB-FL receptors. The selective 
A2AR agonist, CGS21680 (10 nM) (Jarvis et al., 1989) had no effect on the 
magnitude of LTP when it was applied alone to hippocampal slices of 
Mecp2−/y mice 1 h after LTP induction in the first pathway and at least 
30 min before LTP induction in the second pathway; the magnitude of LTP 
in the absence (LTPCTR = 17,51  ±  6.70, n = 7) and presence 
Fig. 4. Acute A2AR Activation restores BDNF effect upon LTP: A shows averaged time courses changes in field excitatory postsynaptic potential (fEPSP) slope induced 
by the θ-burst stimulation in the absence (grey circles) or in the presence (green circles) of the selective A2A receptor agonist, CGS21680 (10 nM) in hippocampal 
slices taken from Mecp2−/y mice (n = 7). CGS21680 (10 nM) was applied 60 min after the induction of LTP in the first pathway (grey circles) and at least 20 min 
before induction of LTP in the second pathway (green circles). B shows time courses changes of averaged fEPSP slopes in response to θ-burst stimulation in the 
absence (grey circles) or presence (red circles) of both CGS21680 (10 nM) and BDNF (20 ng/ml) in hippocampal slices taken from Mecp2−/y animals (n = 6). 
Representative traces from representative experiments are shown. Panel C depicts corresponding LTP magnitudes. All values are mean  ±  standard error of mean 
(SEM). *p  <  0.05 (Student's t-test) #p  <  0.05 (F test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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(LTPCGS = 25.52  ±  5,79, n = 7) of CGS21680 did not significantly differ 
(p = 0.25, paired t-test; Fig. 4A;C). However, in the presence of 
CGS21680, the LTP magnitude (LTPCGS = 25.52  ±  5,79, n = 7) is sig-
nificantly different from the baseline (values obtained before the θ-burst; 
n = 7; p = 0.01, paired t-test, Fig. 4C), in contrast with what occurred in 
the absence of CGS21680. Next, we set to test whether activation of A2AR 
with CGS21680 could rehabilitate the facilitatory effect of BDNF on LTP 
when the neurotrophin was applied in a concentration (20 ng/ml) that was 
devoid of effect in hippocampal slices of Mecp2−/y mice (see Fig. 1D;E). In 
these experiments, LTP was induced in the first pathway in the absence of 
test drugs, then CGS21680 (10 nM) was applied 1 h after induction of the 
first LTP and BDNF (20 ng/ml) was applied 20 min after starting 
CGS21680 perfusion. The second pathway LTP was induced at least 
30 min after starting BDNF application together with CGS21680. Co-ap-
plication of BDNF (20 ng/ml) plus CGS21680 (10 nM) increased the 
magnitude of LTP in the hippocampus of Mecp2−/y mice 
(LTPCTR = 9.6  ±  10.2% vs. LTPCGS+BDNF = 43.9  ±  4.3%, n = 6; 
p = 0.048, paired t-test; Fig. 4B;C); the LTP magnitude attained under 
these conditions was fairly comparable to that obtained with BDNF alone 
in WT animals (see Fig. 1C;E). Data suggest that exogenous activation of 
A2AR with CGS21680 may rehabilitate BDNF signalling deficits observed 
in hippocampal LTP in Mecp2−/y mice, strengthening our theory that in-
adequacy of endogenous adenosine production plays a major role in sy-
naptic transmission deficits in RTT patients. 
4. Discussion 
In the present work, we addressed an innovative strategy to po-
tentiate BDNF effects in RTT through pharmacological modulation of 
adenosine receptors. While evaluating potential causes for the inability 
of exogenous BDNF to facilitate synaptic plasticity, we demonstrated 
that TrkB-FL receptors are decreased in the hippocampus and cerebral 
cortex of symptomatic Mecp2−/y mice and that the adenosinergic 
system is fully dysregulated, both at the receptor expression and func-
tional levels. Pharmacological activation of A2AR was shown to recover 
the facilitatory action of BDNF upon synaptic plasticity. 
BDNF is widely accepted as a neuroprotective molecule and, thus, 
BDNF-based therapies have been thoroughly explored to prevent neu-
rodegeneration (Lu et al., 2013). Although RTT is not considered a 
neurodegenerative disorder, this interest has been extended to RTT 
were BDNF levels are known to be altered mainly in cortex, cerebellum 
and hippocampus (Abuhatzira et al., 2007; Chang et al., 2006; Li et al., 
2012; Wang et al., 2006). A decrease of mRNA BDNF levels in post- 
mortem human brain samples of RTT patients has also been reported 
(Abuhatzira et al., 2007), though differences in BDNF protein levels in 
blood serum and cerebrospinal fluid from RTT human patients have 
been more difficult to show (Riikonen, 2003; Vanhala et al., 1998). 
Much less was known about BDNF receptor signalling in RTT, and 
the existing data were conflicting. One study showed no differences in 
TrkB-FL mRNA levels between human embryonic stem cell derived 
from RTT neurons and controls (Li et al., 2013). Another study 
(Abuhatzira et al., 2007) showed that TrkB-FL mRNA expression levels 
are increased in a mouse model and in RTT human cortical brain 
samples, a change interpreted as a compensatory mechanism for the 
reduced BDNF protein levels detected in whole brain homogenates 
collected from newborn asymptomatic female mutant mice (Abuhatzira 
et al., 2007). By analysing the hippocampus and cortex of symptomatic 
male Mecp2−/y mice separately, we detected a significant decrease of 
BDNF protein levels and a tendency for an increase in mRNA levels of 
TrkB-FL and TrkB-Tc in both brain areas. A tendency for an increase in 
TrkB-FL mRNA in a post-mortem temporal cortex sample from a RTT 
patient was also observed. Importantly, none of the previous studies 
analysed in detail the protein levels of the different isoforms of the TrkB 
receptor, in particular whether putative alterations in the signalling 
form of the TrkB receptor, the TrkB-FL, were accompanied by changes 
in the truncated form of the receptor, the TrkB-Tc form, known to 
counteract TrkB signalling. Our data clearly shows that TrkB-FL protein 
levels are decreased in the hippocampus as well as in the cortex of 
symptomatic Mecp2−/y mice, without appreciable alterations in the 
truncated receptor protein levels. This may alter the way we should 
think about treatment, it is not only important to increase BDNF levels 
but it is also crucial to assure the presence of functional TrkB-FL re-
ceptors. 
The idea that BDNF impairment could contribute to RTT patho-
physiology was greatly reinforced by the finding that BDNF over-
expression could partially ameliorate some of RTT symptoms in 
Mecp2−/y mice, including locomotor function, lifespan and the deficits 
on cortical electrophysiological activity (Chang et al., 2006). Over-
expression of BDNF is, however, of very limited therapeutic use, if 
feasible at all. Other strategies are thus necessary to rescue BDNF 
function and to assure proper levels of TrkB-FL receptor. We aimed to 
potentiate BDNF actions through the major neuromodulator in the 
brain, adenosine. The reason to try this strategy is the previous evi-
dence that, at least in healthy conditions, the synaptic actions of BDNF 
can be potentiated by activation of an adenosine receptor, the A2AR 
(Diógenes et al., 2004). A2AR activation induces transactivation of 
TrkB-FL (Lee and Chao, 2001), promotes translocation of TrkB re-
ceptors to lipid rafts (Assaife-Lopes et al., 2014; Sebastião et al., 2011) 
and regulates BDNF (Tebano et al., 2008) and TrkB-FL (Jerónimo- 
Santos et al., 2014) levels. Moreover, the effect of exogenous BDNF 
upon hippocampal synaptic transmission and LTP is dependent on a 
fully functional adenosinergic tonus via activation of A2AR (Diógenes 
et al., 2011, 2004; Fontinha et al., 2008). However, not all BDNF 
functions are adenosine dependent, which explain why some BDNF 
actions can be revealed even in the presence of and adenosinergic 
dysfunction, as shown in some previous papers (Chang et al., 2006). 
Dysfunction of adenosine signalling has been highlighted in several 
pathologies, such as sleep/arousal dysfunction, neurodegeneration, 
epilepsy, pain, neuronal maturation and central control of breathing 
(Gomes et al., 2011; Ribeiro et al., 2002), but has never been con-
sidered for RTT. This is surprising in light of the putative dual role of 
adenosine in this pathology: on the one hand, and as mentioned above, 
adenosine through A2AR influences BDNF actions; on the other hand, 
adenosine, mostly through A1R, can control seizures in epileptic syn-
dromes such as RTT (Boison, 2007; Sandau et al., 2016). Adenosine is 
an endogenous homeostatic regulator of network activity (Boison, 
2012; Diogenes et al., 2014; Dunwiddie and Masino, 2001) and ade-
nosine deficiency has been identified as a pathologic hallmark of the 
epileptic brain (Aronica et al., 2013). We found that Mecp2−/y mice 
displayed lower tonic inhibitory adenosinergic signalling in the hip-
pocampus, as indicated by: 1) the lower disinhibition of excitatory sy-
naptic transmission while blocking inhibitory A1R; 2) the lower in-
hibition of synaptic transmission caused by an adenosine-releasing 
drug, as an ADK inhibitor; 3) lower levels of adenosine and AMP. This 
lower tonic adenosinergic inhibition is mostly likely due to the de-
creased levels of adenosine which might be related to lower expression 
and/or activity of 5′-nucleotidase resulting in the increased AMP/ade-
nosine concentration ratio detected by us in hippocampus and cortex. 
On contrary, lower tonic adenosinergic inhibition cannot be accounted 
by lower ADK levels since Mecp2−/y mice had maintained ADK protein 
levels. The results obtained with the ADK inhibitor, which caused a 
lower inhibition of synaptic transmission in Mecp2−/y mice, are com-
patible with a lower adenosine gradient across the membrane, thus with 
decreased intracellular adenosine levels in Mecp2−/y mice, highly 
suggestive of dysregulated adenosine homeostasis. Adenosine levels are 
also dependent on ATP levels (Boison, 2015), therefore, we cannot 
exclude the potential role of dysregulated bioenergetics due to dys-
functional mitochondria in RTT. Although lower levels of ATP were 
already reported in the brain of Mecp2−/y mice (Saywell et al., 2006;  
Toloe et al., 2014), in the present work, we did not detected significant 
differences on the content of ATP when comparing hippocampus and 
cortex from WT and Mecp2−/y mice. Interestingly, studies performed in 
C. Miranda-Lourenço, et al.   Neurobiology of Disease 145 (2020) 105043
10
organotypic hippocampal cultures have shown a downregulation on 
mitochondrial gene expression (Großer et al., 2012). Moreover, a 
quantitative decrease in electron transport chain units and reduced 
efficiency of glucose metabolism were found in RTT mouse models (De 
Filippis et al., 2015; Kriaucionis et al., 2006; Saywell et al., 2006). Also 
lower A1R receptor number or lower responsiveness of the A1R did not 
explain lower tonic adenosinergic inhibition because Mecp2−/y mice 
had enhanced A1R protein levels (as revealed by binding assays and 
western blot technique), and the response to an added A1R agonist was 
even higher in slices of Mecp2−/y mice. The mechanism underlying the 
overall increased levels of A1R remains unknown. However, we can 
speculate that this could be a compensatory mechanism to decreased 
levels of adenosine and to the overexcitability associated to this pa-
thology. Indeed, in the brain of Mecp2−/y mice there is a tendency for 
hyperexcitability, associated to changes in basal inhibitory rhythms and 
pre- and postsynaptic defects in GABAergic synapses (Calfa et al., 
2011). Low intracellular adenosine levels may favour DNA methylation 
and hence epileptogenesis (Williams-Karnesky et al., 2013). Conse-
quently, adenosine augmentation therapies constitute an effective 
strategy to reduce seizures, even in cases refractory to conventional 
antiepileptic drugs (Boison, 2013, 2009). 
In contrast with A1Rs, the protein levels of A2AR were decreased in 
cortex of Mecp2−/y mice. The available receptors were nevertheless 
enough to respond to exogenous activation with a selective agonist, 
which was able to rescue the action of BDNF on synaptic plasticity 
(LTP). This further reinforces the hypothesis that adenosine augmen-
tation therapies may be a particularly useful strategy in a disease that 
simultaneously involves low BDNF signalling and low capability of 
endogenous adenosine to act as an endogenous anticonvulsant. As it 
occurred with the mRNA of the A1R, the mRNA expression level of A2AR 
was not significantly affected in Mecp2−/y mice. The discrepancy be-
tween mRNA and protein expression levels could be attributed to sev-
eral posttranscriptional mechanisms such as deregulation of AKT/ 
mTOR in RTT, an important signalling pathway for protein synthesis 
and which it is under the regulatory influence of MeCP2 (Li et al., 
2013). Intriguingly, it was possible to detect changes in the mRNA le-
vels of both A1R and A2AR in one post-mortem human brain sample from 
an RTT patient, and the changes detected closely mimicked the changes 
detected at the protein level in Mecp2−/y mice. The advanced disease 
stage of the donor child and the inherent differences between mice 
models and humans may explain the discrepancy regarding mRNA ex-
pression levels. Nevertheless, we should acknowledge the limitations of 
this analysis: samples from only one mRNA RTT patient were available, 
and it was thus not possible to access variability in different subjects. 
Considering the high influence of the heterozygosity in this syndrome, 
we conducted some preliminary experiences to know if the adenosi-
nergic system is also changed in a milder phenotype such as the het-
erozygotic mice female. The results showed similar changes found in 
the hippocampus from Mecp2−/y: decreased protein levels of A2AR and 
increased protein levels in A1R. Moreover, the alterations detected in 
mRNA expression levels of A2AR and A1R support a similar deregulation 
in adenosinergic system in the sample from a RTT patient with a dif-
ferent genotype (MeCP2 mutation - R255X). These results strongly 
support the hypothesis that the adenosinergic system is changed in 
multiple phenotypes of RTT. Taken together, the results show a de-
crease on endogenous adenosine levels and a consequent impairment 
on adenosinergic signalling in RTT. This deregulation could hamper 
BDNF signalling and may account for epileptogenesis and decrease 
seizure control, therefore opening new avenues for RTT therapy: ade-
nosine augmentation therapies (AAT). AAT have been already explored 
in other pathologies, such as in epilepsy (Boison, 2009). Interestingly, 
RTT patients present some disturbances related with deregulation on 
adenosinergic system such dysfunction in sleep/arousal, neuronal ma-
turation, central control of breathing and epilepsy, (Gomes et al., 2011;  
Ribeiro et al., 2002). Our findings showing alterations in adenosine 
system in RTT strongly point towards a possible contribution of 
adenosine system in RTT pathophysiology. To potentiate BDNF sig-
nalling it could be enough to target only A2AR. However, our results 
shed light into the relevance of using AATs instead of direct A2AR ac-
tivation. IndeeTs would target the two high affinity adenosine receptors 
and trigger their activation to promote: 1) the rescue of BDNF effects, 
through A2AR; 2) the control of hyperexcitability through A1R. In ad-
dition, it was already shown that adenosine plays an important role in 
epileptogenesis through an epigenetic action by DNA methylation, 
which inhibits epileptogenesis (Williams-Karnesky et al., 2013). As 
previous discussed, AAT could be achieved by genetic approaches and 
cell-therapy strategies (as discussed in Boison, 2009). 
Subsequent work should elucidate whether MeCP2 directly affects 
the expression of enzymes that regulate adenosine and adenosine re-
ceptor expression. It is possible that changes in receptor levels result of 
homeostatic mechanisms (Sandau et al., 2016) attempting to preserve 
inhibitory ADO synaptic actions by increasing inhibitory A1R and de-
creasing excitatory A2AR expression levels. However, in the case of RTT 
where BDNF expression and signalling is impaired, the decrease of A2AR 
further aggravates the disease. Importantly, as we herein show, in spite 
of the reduction of A2AR expression and the decreased levels of en-
dogenous adenosine, the pharmacological activation of A2AR could ef-
ficiently rescue BDNF effects upon synaptic plasticity. 
5. Conclusion 
In conclusion, we found that BDNF actions upon hippocampal LTP 
are impaired in RTT. This dysfunction can be explained by the changes 
in TrkB receptor levels and in adenosinergic neuromodulation. 
Importantly, by understanding that the adenosinergic system is com-
promised in RTT, we can now advance that deregulation of BDNF sig-
nalling can also be due to impairment of endogenous A2AR activation. 
This study thus sets the stage for new adenosine-based pharmacological 
therapeutic strategies for RTT, for which disease modifying drugs are 
still lacking. 
Supplementary data to this article can be found online at https:// 
doi.org/10.1016/j.nbd.2020.105043. 
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